secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-218026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M
----------------------------------------------------------------------------

- Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.
- Net loss $26.7M ($1.18/share) vs $26.2M ($1.17/share) in Q2 2021.
- Cash and marketable securities $112.4M as of June 30, 2022.
- Reaffirms FY2022 Jelmyto revenue guidance of $70-80M; reduces operating expense forecast to $130-140M.
- Enrollment in Phase 3 ENVISION trial for UGN-102 on track for completion by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/0001193125-22-218026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/d338870d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-218026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer